Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 2,673 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral capsules Clear all
Completed Phase 2 Interventional

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

NCT00312780
View directory record Official record
Conditions
Albuminuria, Diabetic Nephropathy
Interventions
XL784
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics

NCT03220776
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder
Interventions
N-Acetylcysteine, Gabapentin, Placebo Oral Tablet
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 17, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Silodosin to Facilitate Passage of Urinary Stones

NCT01144949
View directory record Official record
Conditions
Ureteral Calculi, Kidney Stones, Urolithiasis
Interventions
silodosin, placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
27
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mission Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

NCT02045940
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

NCT03140813
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

NCT02003924
View directory record Official record
Conditions
Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
37
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

NCT01376323
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073 1mg, GSK256073 5mg, GSK256073 10mg, GSK256073 25mg, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Anniston, Alabama • Miami, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glyburide Healthy Volunteer Study

NCT01716338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

NCT05424276
View directory record Official record
Conditions
Parkinson Disease
Interventions
IkT-148009 (risvodetinib), Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Reseda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294 Capsule
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Interventions
Ferric maltol, Placebo
Drug · Other
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
27
States / cities
Peoria, Arizona • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

NCT01131013
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Artery Disease
Interventions
Placebo, 375 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tissue Sodium in Pre-hypertensive Patients

NCT02236520
View directory record Official record
Conditions
Hypertension
Interventions
Spironolactone, Chlorthalidone, Diet, Placebo
Drug · Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Human Laboratory Study of Varenicline for Alcohol Use Disorder

NCT03035708
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Varenicline, Placebo oral capsule
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

NCT03573297
View directory record Official record
Conditions
Bipolar I Disorder, Mania, Depression
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 17, 2026, 7:34 PM EDT
Withdrawn Phase 4 Interventional

Guanfacine Extended Release and Mindfulness Skills Therapy

NCT03258476
View directory record Official record
Conditions
Stress Disorder
Interventions
Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

NCT04277910
View directory record Official record
Conditions
Healthy
Interventions
MT2004, Placebo
Drug
Lead sponsor
Xi'an Biocare Pharma Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 17, 2026, 7:34 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

NCT00818389
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Lithium Carbonate, Riluzole, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial Evaluating THB335 in Healthy Participants

NCT06425861
View directory record Official record
Conditions
Healthy
Interventions
THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo
Drug
Lead sponsor
Third Harmonic Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 17, 2026, 7:34 PM EDT